Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab
Public ClinicalTrials.gov record NCT02719613. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab
Study identification
- NCT ID
- NCT02719613
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Enrollment
- 67 participants
Conditions and interventions
Conditions
Interventions
- Bortezomib Drug
- Dexamethasone Drug
- Elotuzumab Drug
- Lenalidomide Drug
- Nivolumab Drug
- Pomalidomide Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 14, 2016
- Primary completion
- Feb 22, 2026
- Completion
- Feb 22, 2026
- Last update posted
- Apr 14, 2026
2016 – 2026
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0020 | Tucson | Arizona | 85715 | — |
| Local Institution - 0017 | Bakersfield | California | 93309 | — |
| Local Institution - 0022 | Fountain Valley | California | 92708 | — |
| Local Institution - 0016 | West Hollywood | California | 90069 | — |
| Local Institution - 0019 | Denver | Colorado | 80218 | — |
| Local Institution - 0021 | Jacksonville | Florida | 32256 | — |
| Local Institution - 0042 | St. Petersburg | Florida | 33705 | — |
| Local Institution - 0009 | Atlanta | Georgia | 30322 | — |
| Local Institution - 0003 | Indianapolis | Indiana | 46260 | — |
| Local Institution - 0002 | Boston | Massachusetts | 02215 | — |
| Local Institution - 0008 | St Louis | Missouri | 63110 | — |
| Local Institution - 0004 | New York | New York | 10029 | — |
| Local Institution - 0001 | Bethlehem | Pennsylvania | 18015 | — |
| Local Institution - 0018 | Dallas | Texas | 75231 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02719613, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 14, 2026 · Synced May 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02719613 live on ClinicalTrials.gov.